- Home
- BFST vs XNCR Comparison
BFST vs XNCR Comparison
Compare BFST & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | XNCR |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BFST | XNCR |
|---|---|---|
| Price | $32.25 | $22.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.75 | $22.33 |
| AVG Volume (30 Days) | 222.0K | ★ 1.2M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 65.36 |
| EPS | ★ 1.37 | N/A |
| Revenue | $10,704,000.00 | ★ $125,576,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | $4.80 |
| P/E Ratio | $23.56 | ★ N/A |
| Revenue Growth | 1.20 | ★ 13.65 |
| 52 Week Low | $22.56 | $7.13 |
| 52 Week High | $32.53 | $23.40 |
Technical Indicators
Market Signals| Indicator | BFST | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.99 | 73.11 |
| Support Level | $29.48 | $11.05 |
| Resistance Level | $32.39 | N/A |
| Average True Range (ATR) | 0.53 | 1.30 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 82.95 | 91.74 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.